Your browser doesn't support javascript.
loading
[EBV-positive central nervous system lymphoproliferative disease associated with immunosuppression after organ transplantation: Long-term remission without chemotherapy]. / Limfoproliferativnoe EBV-pozitivnoe zabolevanie s porazheniem tsentral'noi nervnoi sistemy, assotsiirovannoe s immunosupressiei posle organnoi transplantatsii: dlitel'naia remissiia posle khimioterapevticheskogo lecheniia.
Gavrilina, O A; Troitskaya, V V; Zvonkov, E E; Parovichnikova, E N; Galstyan, G M; Biryukova, L S; Nesterenko, I V; Kovrigina, A M; Bazhenov, A V; Savchenko, V G; Savchenko, V G.
Afiliação
  • Gavrilina OA; National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia.
  • Troitskaya VV; National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia.
  • Zvonkov EE; National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia.
  • Parovichnikova EN; National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia.
  • Galstyan GM; National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia.
  • Biryukova LS; National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia.
  • Nesterenko IV; National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia.
  • Kovrigina AM; National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia.
  • Bazhenov AV; National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia.
  • Savchenko VG; National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia.
  • Savchenko VG; National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia.
Ter Arkh ; 89(7): 69-75, 2017.
Article em Ru | MEDLINE | ID: mdl-28766544
Primary central nervous system (CNS) lymphomas account for 13-20% of the posttransplant lymphoproliferative disorders (PTLD) and rank among the most aggressive conditions. Reduction of immunosuppressive therapy should be mandatory to treat PTLD, but this is rarely used as the only therapy option. Chemotherapy regimens for PTLD involving the CNS most commonly include high-dose rituximab and high-dose methotrexate and/or cytarabine. The efficiency only of discontinuation of immunosuppressive therapy for PTLD does not exceed 5-10%, but there are no literature data on its efficiency for PTLD involving the CNS. The paper describes a clinical case of achieving long-term remission in a female patient with Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma involving the central nervous system, associated with immunosuppression after kidney transplantation from a related donor, in the absence of chemotherapy during immunosuppressive therapy discontinuation and transplantectomy.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfoma Difuso de Grandes Células B / Terapia de Imunossupressão / Transplante de Rim / Herpesvirus Humano 4 / Imunossupressores / Falência Renal Crônica Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Adult / Female / Humans Idioma: Ru Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfoma Difuso de Grandes Células B / Terapia de Imunossupressão / Transplante de Rim / Herpesvirus Humano 4 / Imunossupressores / Falência Renal Crônica Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Adult / Female / Humans Idioma: Ru Ano de publicação: 2017 Tipo de documento: Article